{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T23:09:49Z","timestamp":1649200189070},"reference-count":16,"publisher":"Akademiai Kiado Zrt.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MaSeb"],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:title>Absztrakt<\/jats:title>\n        <jats:p>A Magyarorsz\u00e1gon \u00e9vente 6,5\u20137 ezer ember hal\u00e1l\u00e1t okoz\u00f3 m\u00e1jzsugorod\u00e1s egyik gyakori sz\u00f6v\u0151dm\u00e9nye a hepaticus encephalopathia. Kialakul\u00e1s\u00e1ban jelenlegi ismereteink szerint a sz\u00e9rum-amm\u00f3niaszint n\u00f6veked\u00e9se j\u00e1tszik szerepet, azonban s\u00falyoss\u00e1g\u00e1t egy, a k\u00f6zelm\u00faltban publik\u00e1lt vizsg\u00e1lat alapj\u00e1n a parenchym\u00e1s dekompenz\u00e1ci\u00f3 r\u00e9szek\u00e9nt \u00e9szlelhet\u0151 sziszt\u00e9m\u00e1s gyullad\u00e1sos v\u00e1lasz jelent\u0151sen befoly\u00e1solja. A szerz\u0151k ennek kapcs\u00e1n \u00e1ttekintik \u00e9s elemzik a jelenleg alkalmazott kezel\u00e9si m\u00f3dokat, illetve klinikai vizsg\u00e1latban igazolt jelent\u0151s\u00e9g\u00fcket. A bizony\u00edt\u00e9kon alapul\u00f3 orvosl\u00e1s alapj\u00e1n a jelenleg \u00e1ltal\u00e1nosan elfogadott \u00e9s javasolt peroralis diszacharid-, neomycin- vagy metronidazol-kezel\u00e9s eset\u00e9n csak r\u00e9szlegesen lehetett klinikai hat\u00e9konys\u00e1got igazolni. A jelenleg egyed\u00fcl I. szint\u0171 bizony\u00edt\u00e9kkal b\u00edr\u00f3 rifaximin eset\u00e9n az alkalmaz\u00e1st korl\u00e1toz\u00f3 t\u00e9nyez\u0151 az igen jelent\u0151s kezel\u00e9si k\u00f6lts\u00e9g. A t\u00e9m\u00e1ban 2011 okt\u00f3ber\u00e9ig megjelent publik\u00e1ci\u00f3k feldolgoz\u00e1sa kapcs\u00e1n \u00e9szlelt\u00e9k, hogy nincs egys\u00e9ges ir\u00e1nyelv a hepaticus encephalopathia kezel\u00e9s\u00e9re, noha annak foka szignifik\u00e1nsan meghat\u00e1rozza a m\u00e1j\u00e1t\u00fcltet\u00e9sre v\u00e1r\u00f3 betegek v\u00e1rhat\u00f3 t\u00fal\u00e9l\u00e9s\u00e9t. A feldolgozott forr\u00e1sanyag alapj\u00e1n a szerz\u0151k javaslatot tesznek igazoltan hat\u00e1sos kezel\u00e9si m\u00f3d alkalmaz\u00e1s\u00e1ra, illetve felvetik az egys\u00e9ges kezel\u00e9si elv kialak\u00edt\u00e1s\u00e1nak sz\u00fcks\u00e9gess\u00e9g\u00e9t.<\/jats:p>","DOI":"10.1556\/maseb.65.2012.2.4","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T01:13:24Z","timestamp":1334798004000},"page":"58-62","source":"Crossref","is-referenced-by-count":0,"title":["Hepaticus encephalopathia \u00e9s m\u00e1j\u00e1t\u00fcltet\u00e9s"],"prefix":"10.1556","volume":"65","author":[{"given":"Imre","family":"Feh\u00e9rv\u00e1ri","sequence":"first","affiliation":[{"name":"1 Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika, Semmelweis Egyetem, 1082, Budapest, Baross utca 23\u201325."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs","family":"Nemes","sequence":"additional","affiliation":[{"name":"1 Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika, Semmelweis Egyetem, 1082, Budapest, Baross utca 23\u201325."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9nes","family":"G\u00f6r\u00f6g","sequence":"additional","affiliation":[{"name":"1 Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika, Semmelweis Egyetem, 1082, Budapest, Baross utca 23\u201325."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsa","family":"Gerlei","sequence":"additional","affiliation":[{"name":"1 Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika, Semmelweis Egyetem, 1082, Budapest, Baross utca 23\u201325."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"K\u00f3bori","sequence":"additional","affiliation":[{"name":"1 Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika, Semmelweis Egyetem, 1082, Budapest, Baross utca 23\u201325."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","unstructured":"Eg\u00e9szs\u00e9g\u00fcgyi Miniszt\u00e9rium Szakmai Protokollja. Port\u00e1lis hypertensio. K\u00e9sz\u00edtette: Seb\u00e9szeti Szakmai Koll\u00e9gium 2007. <a href=\"http:\/\/www.eum.hu\/seb-portalis-pdf\">http:\/\/www.eum.hu\/seb-portalis-pdf<\/a>"},{"key":"2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2010.07.045","article-title":"Infection and systemic inflammation, not ammonia, are associated with Grade 3\/4 hepatic encephalopathy, but not mortality in cirrhosis","volume":"54","author":"Shawcross DL","year":"2011","journal-title":"J Hepatology"},{"key":"3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials","volume":"328","author":"Als-Nielsen B","year":"2004","journal-title":"BMJ"},{"key":"4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/hep.1840150209","article-title":"Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta-analysis","volume":"15","author":"Blanc P","year":"1992","journal-title":"Hepatology"},{"key":"5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/BF01308097","article-title":"Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: A randomized clinical study","volume":"26","author":"Orlandi F","year":"1981","journal-title":"Dig Dis Sci"},{"key":"6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin Treatment in Hepatic Encephalopathy","volume":"362","author":"Bass NM","year":"2010","journal-title":"N Eng Med J"},{"key":"7","first-page":"321","article-title":"Rifaximin a hepaticus encephalopathia kezel\u00e9s\u00e9ben","volume":"14","author":"Szalay F","year":"2004","journal-title":"LAM"},{"key":"8","first-page":"4","article-title":"Treatment of hepatic encephalopathy with rifaximin: Double blind, double dummy study versus lactulose","volume":"4","author":"Massa P","year":"1993","journal-title":"Eur J Clin Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1016\/j.transproceed.2010.09.173","article-title":"Rifaximine for the Treatment of Hepatic Encephalopathy","volume":"42","author":"Mantry PS","year":"2010","journal-title":"Transpl Proc"},{"key":"10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/TP.0b013e3181d2fe66","article-title":"Considerations on the Impact of Hepatic Encephalopathy Treatments in the Pretransplant Setting","volume":"89","author":"Teperman LW","year":"2010","journal-title":"Transplantation"},{"key":"11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study","volume":"25","author":"Kircheis G","year":"1997","journal-title":"Hepatology"},{"key":"12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","article-title":"Oral L-ornithine L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo- controlled double-blind study","volume":"28","author":"Stauch S","year":"1998","journal-title":"J Hepatol"},{"key":"13","first-page":"726","article-title":"Efficacy of Albumin Dialysis (MARS) in Patients with Cirrhosis and Advanced Grades of Hepatic Encephalopathy: A Prospective, Controlled, Randomized Multicenter Trial","volume":"40","author":"Hassanein T","year":"2004","journal-title":"Hepatology"},{"key":"14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/hep.21930","article-title":"Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis","volume":"46","author":"Hassanein T","year":"2007","journal-title":"Hepatology"},{"key":"15","first-page":"1747","article-title":"Hepaticus encephalopathia korszer\u0171 kezel\u00e9se","volume":"34","author":"Szalay L","year":"2004","journal-title":"Orv Hetil"},{"key":"16","unstructured":"EASL Annual report 2010. <a href=\"http:\/\/www.easl.eu\/assets\/application\/annual\/docs\/e96ef94a666b02c_file.pdf\">http:\/\/www.easl.eu\/assets\/application\/annual\/docs\/e96ef94a666b02c_file.pdf<\/a>"}],"container-title":["Magyar Seb\u00e9szet"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/1046\/65\/2\/article-p58.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/maseb.65.2012.2.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:59:46Z","timestamp":1590141586000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/maseb.65.2012.2.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":16,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1556\/maseb.65.2012.2.4","relation":{},"ISSN":["0025-0295","1789-4301"],"issn-type":[{"value":"0025-0295","type":"print"},{"value":"1789-4301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,1]]}}}